Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

European Ombudsman

- PMLiVE

AbbVie/Genmab’s Epkinly granted FDA accelerated approval to treat follicular lymphoma

Approximately 15,000 people develop the form of non-Hodgkin lymphoma every year in the US

- PMLiVE

AbbVie’s IL-23 inhibitor Skyrizi approved by FDA to treat ulcerative colitis in adults

The inflammatory bowel disease affects more than one million people in the US

tijana being interviewed

Envision Analogue – An Introduction

Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...

Genesis Research Group

- PMLiVE

AbbVie gains rights to FutureGen’s inflammatory bowel disease candidate in deal worth $1.7bn

The agreement gives AbbVie exclusive global rights to the TL1A-targeting monoclonal antibody

- PMLiVE

AstraZeneca’s Tagrisso combination receives CHMP recommendation for advanced lung cancer

More than 450,000 people are diagnosed with lung cancer every year in Europe

- PMLiVE

Pfizer’s one-time haemophilia B therapy Durveqtix receives CHMP recommendation

More than 38,000 people worldwide are currently affected by the inherited bleeding disorder

- PMLiVE

AbbVie shares positive results for Rinvoq in head-to-head atopic dermatitis study

An estimated 10% of adults and 24.6% of adolescents are affected by the inflammatory skin condition

- PMLiVE

AbbVie’s oral therapy Aquipta recommended by NICE for migraine prevention in adults

Approximately 170,000 patients in England are expected to benefit from the agency’s decision

- PMLiVE

AbbVie to expand inflammatory and autoimmune disease portfolio with $212.5m Landos acquisition

The deal will advance the clinical development of NX-13 for patients living with ulcerative colitis and Crohn’s disease

- PMLiVE

AbbVie’s Elahere granted full FDA approval for previously-treated ovarian cancer

The company recently gained access to the therapy through its $10.1bn acquisition of ImmunoGen

- PMLiVE

AbbVie and Parvus Therapeutics collaborate to develop treatments for inflammatory bowel disease

Both companies will utilise Parvus’ Navacim Treg immune tolerisation platform technology

- PMLiVE

AbbVie gains rights to OSE’s chronic inflammation therapy in deal worth $713m

The company will gain an exclusive global license to develop, manufacture and commercialise OSE-230

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links